Cargando…
Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
Empagliflozin is a SGLT2 inhibitor that has shown remarkable cardiovascular and renal activities in patients with type 2 diabetes (T2D). Preclinical and clinical studies of empagliflozin in T2D population have demonstrated significant improvements in body weight, waist circumference, insulin sensiti...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117073/ https://www.ncbi.nlm.nih.gov/pubmed/34027215 http://dx.doi.org/10.5114/amsad.2021.105314 |